A prospective study of endogenous serum hormone concentrations and breast cancer risk in post-menopausal women on the island of Guernsey. by Thomas, H. V. et al.
British Journal ofCancer(1997) 76(3), 401-405
© 1997 Cancer Research Campaign
A prospective study of endogenous serum hormone
concentrations and breast cancer risk in post-
menopausal women on the island of Guernsey
HV Thomas', TJ Key', DS Allen2, JW Moore2, M Dowsett3, IS Fentiman4 and DY Wang5
'Imperial Cancer Research Fund Cancer Epidemiology Unit, Gibson Building, Radcliffe Infirmary, Oxford OX2 6HE, UK; 21mperial Cancer Research Fund,
Lincoln's Inn Fields, London WC2A 3PX, UK; 3Department of Academic Biochemistry, Royal Marsden Hospital, London SW3 6JJ, UK; 41mperial Cancer
Research Fund Oncology Unit, Guy's Hospital, London SE1 9RT, UK; 5Unit of Metabolic Medicine, St Mary's Hospital Medical School, London W2 1PG, UK
Summary The associations between serum concentrations of oestradiol, testosterone and sex hormone-binding globulin (SHBG) and risk of
breast cancer in post-menopausal women were investigated in a prospective study on the island of Guernsey. Sixty-one women who
developed breast cancer an average of 7.8 years after blood collection were matched for age, year of blood collection and number of years
post-menopausal with 179 control subjects. Women using exogenous hormones at the time of blood collection were excluded from the
study. Women who subsequently developed breast cancer had a 29% higher geometric mean oestradiol concentration than control women
(P = 0.004). The odds ratio for breast cancer in the top third compared with the lowest third of the oestradiol concentration distribution was
5.03 (95% confidence interval 2.02-12.49, Pfortrend < 0.001). Adjusting fortestosterone and SHBG concentrations did notsubstantially alter
the odds ratio for oestradiol. Although testosterone and SHBG concentrations were associated with breast cancer risk, the concentrations of
these hormones were correlated with those of oestradiol; the associations were not statistically significant after adjusting for oestradiol
concentration. These data provide evidence that serum oestradiol concentrations in post-menopausal women may have a substantial effect
on breast cancer risk.
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Several areas of research have shown that sex hormones are
involved in the aetiology ofbreast cancer; epidemiological studies
have reported that the presence of functioning ovaries increases
risk; laboratory studies have shown that hormones (particularly
oestrogens) control the growth of breast epithelial cells; and clin-
ical studies have demonstrated that hormones affect the course of
established disease. This knowledge has generated the hypothesis
that high serum concentrations of endogenous oestradiol increase
breast cancer risk (Henderson et al, 1982). The results of
case-control and prospective studies of oestradiol concentrations
among premenopausal women have been inconsistent (Key and
Pike, 1988), perhaps because of the large variation in concentra-
tions over the menstrual cycle and thus the difficulty inclassifying
a woman's usual serum concentration of oestradiol by a single
measurement. By contrast, the results from case-control and
prospective studies ofpost-menopausal women have been reason-
ably consistent in supporting the hypothesis (Wysowski et al,
1987; Key and Pike, 1988; The Anglo-Egyptian Health
Agreement Collaborative Study, 1988; Bernstein et al, 1990;
Blankenstein et al, 1992; Garland et al, 1992; Zaridze et al, 1992;
Helzlsouer et al, 1994; Toniolo et al, 1995; Berrino et al, 1996;
Dorgan et al, 1996) but cannot be regarded as conclusive as most
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ofthe studies are small and only a few are prospective in nature.
Testosterone concentration may also affect breast cancer risk
eitherby directly stimulating thegrowth oftestosterone-dependent
breast cancer cells or by aromatization to oestradiol (Secreto and
Zumoff, 1994). The concentration of sex hormone-binding glob-
ulin (SHBG) is an important determinant of the proportion of
oestradiol and testosterone that is non-protein bound, which is
thought to be the bioavailable fraction (Siiteri et al, 1981).
Therefore, relatively high concentrations of SHBG might reduce
breast cancer risk (Moore et al, 1986).
We report here the results of a moderately large prospective
study designed to investigate associations between endogenous
hormone concentrations and breast cancer risk in post-menopausal
women on the island ofGuernsey. We have specifically tested the
hypotheses that serum oestradiol and testosterone concentrations
are positively associated with breast cancer risk, while serum
SHBG concentration is negatively associated with risk. Results for
urinary oestrogen excretion for 31 ofthese cases, which showed a
significantly higher mean excretion rate for the sum of oestrone,
oestradiol and oestriol in the cases than in the controls, have
recently been published (Key et al, 1996).
SUBJECTS AND METHODS
Study subjects and data collection
Between 1977 and 1990, 6127 women aged 34 years and above
who lived on Guernsey were recruited into a prospective study of
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Table 1 Characteristics of breast cancer cases and controls
Cases Controls P-value
(n = 61) (n = 179)
Mean (s.e.) age at interview (years) 58.6 (0.7) 58.5 (0.4) 0.94
Mean (s.e.) age at menarche (years) 13.7 (0.2) 13.3 (0.1) 0.09
Mean (s.e.) age at menopause (years)a 50.5 (0.4) 50.2 (0.2) 0.59
Mean (s.e.) body mass index (kg m-2)b 26.0 (0.4) 25.6 (0.3) 0.52
Per cent (s.e.) parous 77.0 (5.4) 85.5 (2.6) 0.18
Per cent (s.e.) reporting first-degree family history 14.8 (4.5) 10.7 (2.3) 0.53
Per cent (s.e.) reporting past hormone used 18.3 (5.0) 24.9 (3.3) 0.39
Per cent (s.e.) reporting current drug usee 37.3 (6.3) 46.6 (3.7) 0.27
aData for 57 cases and 168 controls. bData for 178 controls. cFamily history of breast cancer, data for 178 controls. dNot including oral
contraceptives, data for 60 cases and 177 controls. eUse of non-hormonal prescribed or over-the-counter medication at time of interview, data for 59
cases and 178 controls. All P-values are for differences between means or between proportions.
serum hormone concentrations and risk of developing breast
cancer. Recruitment was in two phases, from 1977 to 1985 and
from 1986 to 1990; 3680 women participated in both recruitment
phases. Participants completed a questionnaire at interview, height
and weight were measured and a blood sample was taken. Serum
was stored in 2-ml aliquots at-20°C.
Follow-up for the diagnosis of breast cancer was through
pathology reports (all dealt with by one pathology laboratory),
general practitioners, Guernsey death certificates and the Wessex
Cancer Registry. This registry covers Southampton where some
patients from Guernsey are referred for hospital treatment. Cases
were all women diagnosed with breast cancer subsequent to
recruitment up until the end ofOctober 1994.
Women were eligible for this analysis if they were naturally
post-menopausal (defined as at least 1 year since their last
menstrual period) orifthey hadundergone ahysterectomy without
bilateral oophorectomy before menopause and were aged over 60
at recruitment (three cases and ten control subjects). Women were
excluded if they were using any exogenous sex hormones at the
time ofblood collection or ifthey had previously had cancer other
than non-melanoma skin cancer.
Cases were ordered by age, and potential controls were identi-
fied who matched these ordered cases on age (within 2 years) and
date of blood collection (within 1 year). Naturally post-
menopausal cases were also matched to controls on number of
years post-menopausal, in categories of 1-2 years or 3+ years, but
this matching was relaxed in five instances when a naturally post-
menopausal case was matched to a control who had had a
hysterectomy. The three cases who had undergone a hysterectomy
were matched to controls on this criterion when possible, but when
it was not possible the matched controls were 3+ years naturally
post-menopausal as all were aged over 60 at recruitment. Controls
were also not known to have died or to have been diagnosed with
breast cancer at the date ofdiagnosis oftheir matched case. Three
controls were randomly selected from all those who were suitably
matched. Once a control had been assigned to a case, she was
unavailable for matching with further cases. Serum was available
for 61 cases (unavailable for one eligible case) and for 179
controls (for four cases, only two, controls were available).
Testosterone concentrations were measured for all these women,
oestradiol concentrations were measured for all but one case and
one control and SHBG concentrations were measured for all but
two cases and two controls.
Measurement of serum hormone concentrations
The samples were thawed on the day ofthe testosterone assay, and
an aliquot was removed and refrozen for the oestradiol assay to be
performed at a later date. Samples for matched case-control sets
were analysed blind to case-control status in the same assay batch.
Concentrations of oestradiol were measured in 1995 by
radioimmunoassay after ether extraction (Dowsett et al, 1987).
The intra- and interassay coefficients ofvariation were 11.8% and
15.1%, respectively, at a concentration of 36.4 pmol 1-'. The
lowest detectable concentration was 3.0 pmol 1-1.
Concentrations of testosterone were measured in 1995 using a
radioimmunoassay kit (Immunodiagnostic Systems, Tyne and
Wear, UK). The intra- and interassay coefficients ofvariation were
7.0% and 4.5%, respectively, at a concentration of 2.10 nmol 1-'.
The lowest detectable concentration was 0.35 nmol 1-'.
SHBG was measured in virtually all of the blood samples from
the Guernsey cohort as the study progressed. For samples from the
first recruitment phase (1977-85), concentrations were measured
in 1984-86 by an in-house liquid phase immunoradiometric assay
(Hammond et al, 1985); the intra- and interassay coefficients of
variation were 5.3% and 4.1%, respectively, at a concentration of
76.1 nmol 1-l. In the second recruitment phase (1986-90), the same
method was used in kit form (Farmos Diagnostica, Oulansalo,
Finland) with similar precision.
Twenty-four cases and 64 controls participated in both recruit-
ment phases and had hormone results from two blood samples.
The mean interval between drawing these two blood samples was
8 years (range 5-12 years). The intraclass correlation coefficients
demonstrated good reproducibility of hormone measurements in
the 64 controls: oestradiol, 0.56; testosterone, 0.57; and SHBG,
0.63 (all P < 0.001). Hormone measurements in the blood samples
donated at the first interview have been used in the analyses for
these 88 women. The analyses were repeated using the blood
samples donated at the second interview, and the results were of
the same order and statistical significance as those presented.
Examination by linear regression of the relationship between
oestradiol and testosterone concentrations and duration of blood
sample storage showed that oestradiol concentrations increased by
3% per year ofstorage while testosterone concentrations increased
by 5% per year (P < 0.001 in both cases). A similar relationship
had been noted previously for SHBG (Moore et al, 1987), but the
duration of storage before SHBG assays was relatively short. The
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Table 2 Serum sex hormone concentrations in cases and controls
Cases Controls
Hormone n Geometric mean 95% Cl n Geometric mean 95% Cl P-value
Oestradiol (pmol 1-') 60 49.1 42.4-56.9 175 38.2 35.1-41.7 0.004
Testosterone (nmoll-') 61 1.15 1.02-1.29 179 0.94 0.88-1.01 ' 0.005
SHBG (nmol 1-') 59 52.0 46.2-58.4 171 59.4 55.5-63.6 0.053
Values are geometric means adjusted for duration of blood storage (oestradiol and testosterone only) and number of years post-menopausal. All P-values are
for differences between means.
cause of these relationships is not known, but this phenomenon
does not affect the case-control comparisons because cases and
controls were matched for year ofblood collection.
Statistical analysis
Concentrations ofoestradiol, testosterone and SHBG were logarith-
mically transformed to produce approximately normal distributions,
and the mean hormone concentrations presented are geometric
means. Associations between the natural log ofhormone concentra-
tions and other variables in the controls were explored using partial
correlation coefficients and analysis ofcovariance. Geometric mean
concentrations of the hormones in the cases and controls were
calculated and compared using analysis ofcovariance. The associa-
tions between oestradiol and testosterone concentrations and other
variables, and the comparison oftheir mean concentrations between
cases and controls were adjusted for number of years post-
menopausal and for duration of blood storage. The associations
between SHBG concentration and other variables, and the compar-
ison of its mean concentration in cases and controls were adjusted
for number of years post-menopausal only.
Odds ratios for breast cancer in thirds of the distribution of
hormone concentrations in the controls were calculated for
matched case-control sets using conditional logistic regression,
with the lowest concentration third as a reference. The significance
oflinear trends wasjudged by likelihood ratio tests, with the thirds
of the distribution scored as 1, 2 and 3. The odds ratio analyses
were adjusted separately for age at menarche, parity, number of
years post-menopausal, body mass index (BMI, kg m-2) and the
other hormone concentrations, and they were also adjusted simul-
taneously for all these variables.
Ninety-five per cent confidence intervals and two-sidedP-values
are quoted. Statistical tests were considered significant atP < 0.05.
The EGRET statistical package (Statistics and Epidemiology
Research Corporation and Cytel Software Corporation, Seattle,
WA, USA) was used for conditional logistic regression, all other
analyses were performed using SPSS (SPSS, Chicago, IL, USA).
RESULTS
Diagnosis ofbreast cancer was a mean of7.8 years (range < 1-16
years) subsequent to recruitment. Cases and controls were similar
in mean ages at interview (a matching criterion) and at menopause
(Table 1). Cases were, on average, 5 months older at menarche than
the controls and had a 1.6% higher mean BMI. A lower proportion
of cases than controls was parous and a higher proportion of cases
reported a first-degree family history of breast cancer. A smaller
proportion of cases than controls reported past use of any hormonal
treatment (not including oral contraceptives) and use of any other
prescribed or over-the-counter medication at the time ofinterview.
None ofthese differences was statistically significant.
Associations between hormones and other variables in
controls
Oestradiol concentration increased significantly with increasing
testosterone concentration and increasing BMI (correlation coeffi-
cients 0.52 and 0.33 respectively; P < 0.01 forboth) and decreased
significantly with increasing number of years since menopause
(correlation coefficient -0.19; P = 0.01). Testosterone concentra-
tion decreased significantly with increasing age at interview
(correlation coefficient = -0.21; P < 0.01). SHBG concentration
decreased significantly with increasing BMI (correlation coeffi-
cient = -0.38; P < 0.01). There were no significant associations
between the hormone concentrations and age at menarche, parity,
first-degree family history of breast cancer, past exogenous
hormone use or use of prescribed or over-the-counter medication
at the time ofinterview (results not shown).
Hormone concentrations in cases and controls
In comparison with the 179 controls, the 61 breast cancer cases
had a 29% higher geometric mean oestradiol concentration (P =
0.004), 22% higher testosterone (P = 0.005) and 12% lower SHBG
(P = 0.053) (Table 2). These results were adjusted for number of
years post-menopausal and duration of blood storage (oestradiol
and testosterone only), although the unadjusted results were
extremely similar as these covariates were matching criteria.
The unadjusted odds ratios in the middle and upper thirds ofthe
oestradiol distribution were 2.54 and 5.03 respectively (P fortrend
< 0.001) (Table 3). Adjusting separately for testosterone and
SHBG did not substantially alter these odds ratios.
The unadjusted odds ratios in the middle and upper thirds ofthe
testosterone distribution were 1.83 and 2.39 respectively (P for
trend = 0.045). Adjusting for oestradiol concentration reduced
these odds ratios to 1.10 and 0.82 (P for trend = 0.657). Adjusting
separately for SHBG had little effect on the results.
The unadjusted odds ratios in the middle and upper thirds ofthe
SHBG distribution were 1.15 and 0.37 respectively (P for trend =
0.037). After adjusting for oestradiol, the trend was no longer
statistically significant. Adjusting separately for testosterone had
little effect on the results.
Adjusting either separately or simultaneously for age at
menarche, parity, number of years post-menopausal and BMI did
not affect the results for any of the hormones. The odds ratio
analyses were repeated excluding seven cases who donated blood
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Table 3 Odds ratios for breast cancer in relation to serum hormone concentrations
Odds ratio (95% Cl)
Hormone No. of No. of Unadjusted Adjusted for Adjusted for Adjusted for
cases controls oestradiol testosterone SHBG
Oestradiol (pmol l-1)
< 30.7 7 57 1.00 NAa 1.00 1.00
30.7-41.0 19 61 2.54 (1.00-6.44) 2.59 (0.92-7.28) 2.13 (0.83-5.42)
>41.0 34 57 5.03 (2.02-12.49) 5.62 (1.87-16.87) 4.94 (1.94-12.55)
(P< 0.001) (P< 0.001) (P< 0.001)
Testosterone (nmol 1-')
< 0.73 13 59 1.00 1.00 NAa 1.00
0.73-1.25 22 61 1.83 (0.82-4.12) 1.10 (0.43-2.77) 1.54 (0.68-3.53)
>1.25 26 59 2.39 (1.01-5.65) 0.82 (0.28-2.42) 2.34 (0.98-5.59)
(P= 0.045) (P= 0.657) (P= 0.048)
SHBG (nmol 1-1)
< 48.0 24 57 1.00 1.00 1.00 NAa
48.0-77.7 26 57 1.15 (0.57-2.31) 1.33 (0.63-2.80) 1.14 (0.56-2.31)
>77.7 9 57 0.37 (0.15-0.89) 0.41 (0.17-1.03) 0.38 (0.16-0.93)
(P= 0.037) (P= 0.089) (P= 0.046)
aOdds ratios estimated by conditional logistic regression for matched case-control sets. All P-values are for linear trend for thirds scored as 1, 2, 3.
less than 2 years before diagnosis (and their matched controls) and
the resulting odds ratios were not substantially altered. The
analyses were also repeated excluding three cases (and their
matched controls), together with a further five control subjects
who had undergone a hysterectomy. Again the results did not
differ markedly from those presented. Odds ratios were also calcu-
lated using the distribution of the hormone concentrations in the
controls divided into quarters (instead of thirds) to assess the
robustness ofthe data and again similar results were noted.
DISCUSSION
The most striking finding from this study is the sharp gradient of
risk ofbreast cancer with serum oestradiol concentrations in post-
menopausal women, with the upper third of the distribution
approximately five times more likely (95% confidence interval
approximately 2-12 times more likely) to develop breast cancer
than those with oestradiol concentrations in the lowest third. The
blood samples were collected a mean of 7.8 years before diag-
nosis, and restriction ofthe analyses to cases who donated blood 2
or more years before diagnosis produced results similar to those
cited. It is therefore unlikely that the differences reported in serum
hormone concentrations are due to metabolic effects of early
cancer. We conclude that serum oestradiol concentrations in post-
menopausal women may be a strong predictor of the subsequent
risk ofdeveloping breast cancer.
Four other prospective studies (Helzlsouer et al, 1994; Toniolo
et al, 1995; Berrino et al, 1996; Dorgan et al, 1996) have also
reported an association between relatively high serum concentra-
tions of oestradiol and increased risk of breast cancer, while two
others have reported results that appear negative but that may be
statistically compatible with ours (Wysowski et al, 1987; Garland
et al, 1992). Our study benefits from the combination of (1) using
a highly specific and sensitive assay that had been optimized for
measuring post-menopausal levels of oestradiol, (2) the inclusion
of a relatively large sample size and (3) having a long follow-up
period. Theresulting data strongly confirm the previouslyreported
association between endogenous oestradiol and breast cancer risk.
The concentration of SHBG is an important determinant of the
proportion of oestradiol that is non-protein bound, which is
thought to be the bioavailable fraction (Siiteri et al, 1981).
However, studies investigating the importance of SHBG in the
aetiology of breast cancer have reported inconsistent findings
(Key and Pike, 1988). None of the four prospective studies that
measured SHBG concentration has reported a significant associa-
tion with breast cancer risk (Garland et al, 1992; Helzlsouer et al,
1994; Berrino et al, 1996; Dorgan et al, 1996). We report some
evidence of a trend for a decrease in breast cancer risk as SHBG
concentrations increase. As the mean concentration of SHBG is
lower in the cases, one might expect higher percentages of non
protein-bound oestradiol in the cases than in the controls, as previ-
ously reported in the Guernsey cohort (Moore et al, 1986).
Several case-control studies (Grattarola et al, 1974; McFadyen
et al, 1976; Adami et al, 1979; Secreto et al, 1983; Hill et al, 1985;
Secreto et al, 1991) have reported that a significantly increased
risk ofbreast cancer in post-menopausal women is associated with
high levels of testosterone in serum and urine. The prospective
studies of Berrino et al (1996) (24 cases) and Dorgan et al (1996)
(71 cases) both reported a significant association between breast
cancer risk and total testosterone concentration, quoting adjusted
odds ratios of7.0 and 6.2, respectively, for the top category ofthe
concentration distribution. In contradiction to our results, Berrino
et al (1996) found that the odds ratio foroestradiol decreased when
adjusted for (free) testosterone, while adjustment for total oestra-
diol increased the association between breast cancer risk and
levels of total testosterone. The follow-up period in both these
studies was short, with a mean of 3.5 years reported by Berrino et
al (1996) and a median of 2.9 years reported by Dorgan et al
(1996). Restriction of the analyses by Dorgan et al (1996) to 46
cases whose blood was collected more than 2 years before diag-
nosis reduced the odds ratio in the top tertile of the testosterone
distribution to 1.3, which was no longer statistically significant.
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In our data, the association between testosterone and breast
cancer risk exists more than 2 years before diagnosis. However,
this association may not be directly causal, instead it might be an
indirect consequence of testosterone acting as a precursor to
oestradiol or may be as a result of the strong correlation between
the two hormones; our results suggest that oestradiol is indepen-
dently associated with breast cancer risk but testosterone is not.
More data on endogenous sex hormones need to be collected from
further large prospective studies after a long follow-up period, but
the evidence that endogenous oestradiol concentration is related to
breast cancer risk in post-menopausal women is becoming strong.
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